Nexalin Technology reports benefit of Gen-2, 15 mA device for TRD

Nexalin Technology reported the results of a study in patients with treatment-resistant depression TRD, concerning the potential therapeutic benefits of its second-generation Gen-2, 15 milliampor mA, neurostimulation device, which indicated a substantial and statistically significant benefit in patients. The clinical trial was funded by the Company’s joint venture partner, Wider Come Limited, and its related companies, and was conducted at the Xuanwu Hospital, Capital Medical University in Beijing, China. The results were also published in General Psychiatry, an open-source, peer-reviewed scientific journal. The published results of the study concluded that repeated treatment with Nexalin’s neurostimulation device suggests an acute effect in reducing depressive symptoms in patients with TRD. In addition, no adverse events were observed during treatment…Mark White, CEO of Nexalin Technology, stated, “We are pleased to report the results of this study in patients with treatment-resistant depression TRD , which have been featured in a leading peer-reviewed journal. These results reinforce the growing body of clinical evidence supporting the potential of Nexalin’s new advanced waveform to help combat the ongoing global mental health epidemic. We believe the data provides further evidence of the significant impact of our non-invasive, drug-free device on improving mental healthcare outcomes among patients affected with TRD. No significant adverse effects were reported, which is especially noteworthy given the growing number of patients seeking non-pharmacological treatment options. Overall, we remain committed to our mission of bringing our new, effective, and drug-free therapy to patients with mental health issues in the United States and around the world.”